Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.38%
0%
23.38%
6 Months
-51.53%
0%
-51.53%
1 Year
-66.67%
0%
-66.67%
2 Years
-96.42%
0%
-96.42%
3 Years
-97.55%
0%
-97.55%
4 Years
-98.62%
0%
-98.62%
5 Years
-98.65%
0%
-98.65%
GeNeuro SA (Switzerland) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.36%
EBIT to Interest (avg)
-16.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0
Tax Ratio
4.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.08
EV to EBIT
-0.43
EV to EBITDA
-0.44
EV to Capital Employed
-0.78
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.80
-7.20
-77.78%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.20
-6.80
-79.41%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -79.41% vs 24.44% in Dec 2021
About GeNeuro SA (Switzerland) 
GeNeuro SA (Switzerland)
Pharmaceuticals & Biotechnology
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Company Coordinates 
Company Details
3, Chemin du Pre-Fleuri , PLAN-LES-OUATES None : 1228
Registrar Details






